VEGFR2/CD309 antibody (Extracellular Domain)

Catalog No. ABIN115682

Product Details anti-VEGFR2/CD309 Antibody

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Binding Specificity: Extracellular Domain

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This VEGFR2/CD309 antibody is un-conjugated

Application: Western Blotting (WB), Immunoprecipitation (IP), Immunohistochemistry (Frozen Sections) (IHC (fro)), Enzyme Immunoassay (EIA), Functional Studies (Func)

Specificity: The polyclonal antibody will detect native and recombinant Human VEGFR-2/KDR in ELISA experiments and on the surface or solubilized from different Human cell types.

Cross-Reactivity (Details): Species reactivity (tested):Human.

Purification: Protein A Affinity Chromatography

Immunogen: Recombinant Human soluble extracellular domain of KDR protein (D1-7). Remarks: The antibody is identical with the former described antibody r212 (see Lit.)

Application Details

Application Notes: ELISA: Use at 5-15 μg/mL. Western blotting: Use at 10-20 μg/mL. Immunoprecipitation: Use 1-2 μg/mg protein lysate. Neutralizing experiments: Depending on the conditions and ligand concentration startwith 25-50 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Reconstitution: Restore in sterile water to a concentration of 1.0 mg/mL.

Buffer: PBS, pH 7.4 without preservatives or stabilizers

Preservative: Without preservative

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: The lyophilized antibody, thought stable at room temperature, is best stored desiccated below 0 °C. Reconstituted anti-VEGFR-2/KDR is stable at 2-8 °C for one month or can be stored in working aliquots at -20 °C for more than six months.

Target Details for VEGFR2/CD309

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Alternative Name: CD309 / VEGFR-2 / Flk-1 (VEGFR2 Products)

Synonyms: CD309 antibody, FLK1 antibody, VEGFR antibody, VEGFR2 antibody, 6130401C07 antibody, Flk-1 antibody, Flk1 antibody, Krd-1 antibody, Ly73 antibody, VEGFR-2 antibody, sVEGFR-2 antibody, Vegfr-2 antibody, FLK-1 antibody, flk-1 antibody, vegfr-2 antibody, KDR antibody, FLK/KDR antibody, flk1 antibody, flk1b antibody, kdrb antibody, si:busm1-205d10.1 antibody, si:ch211-254j6.1 antibody, si:ch211-278f21.4 antibody, wu:fc31a09 antibody, fk52c05 antibody, flk antibody, kdr antibody, kdra antibody, vegfr2 antibody, vegfr4 antibody, vegr2 antibody, wu:fk52c05 antibody, kinase insert domain receptor antibody, kinase insert domain protein receptor antibody, vascular endothelial growth factor receptor kdr-like antibody, kinase insert domain receptor (a type III receptor tyrosine kinase) antibody, kinase insert domain receptor like antibody, KDR antibody, Kdr antibody, LOC100136647 antibody, kdr antibody, kdrl antibody

Background: VEGF receptor 2 is a member of a receptor tyrosine kinase family whose activation plays an essential role in a large number of biological processes such as embryonic development, wound healing, cell proliferation, migration and differentiation. Like other growth factor receptors, upon ligand binding VEGF receptor 2 dimerises and is autophosphorylated on multiple tyrosine residues. These sites can be involved in the regulation of kinase activity or serve as binding sites for SH2 and phosphotyrosine binding containing signalling proteins. Phosphorylation of Tyrosines 1054 and 1059 in the activation loop is required for activation of VEGF receptor 2 and its intrinsic tyrosine kinase activity. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.Synonyms: FLK1, KDR, Kinase NYK, Kinase insert domain receptor, Protein-tyrosine kinase receptor Flk-1, VEGF Receptor 2, VEGFR2, Vascular endothelial growth factor receptor 2

Gene ID: 3791

NCBI Accession: NP_002244

UniProt: P35968

Pathways: RTK Signaling, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling